By Kosaku Narioka
Takeda Pharmaceutical Co. said Thursday its second-quarter net profit rose 34% from the same period a year earlier on improved sales in the United States and other international markets.
The Japanese drugmaker said net profit for the quarter ended Sept. 30 rose to 61.7 billion yen ($421.5 million). That was below the 84.81 billion yen estimate from an analyst poll by Visible Alpha.
Second-quarter revenue increased 19% from a year earlier to 1,002,000 billion yen on gains in markets outside of Japan.
U.S. revenue rose to 531.5 billion yen from 426.2 billion yen, while Japan’s revenue fell to 120.8 billion yen from 131.9 billion yen.
Drug sales increased in various business sectors. Sales of ulcerative colitis drug Entyvio rose 37% from a year earlier to 178.3 billion yen, while sales of plasma-derived products rose 32% to 172.1 billion of yen.
Takeda raised its revenue and net profit forecast for the fiscal year ending March 2023. It expects revenue to rise 10% to 3.93 trillion yen, compared to its previous forecast of an increase of 3.4%, and it expects its net income to increase by 33%. to 307.00 billion yen, compared to the previous forecast of a 27% increase.
Write to Kosaku Narioka at [email protected]